文献类型：期刊文献

英文题名：Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles

作者：Niu, Jinping[1];Zhao, Zhangting[1];Zhang, Tong[2];Liu, Qingwei[2];Huang, Liyao[2];Li, Shipo[1];Liu, Haipeng[3];Yu, Shaowen[4];Li, Linfeng[1,5];Jia, Hao[5];Zheng, Wenyun[2];Yang, Feng[6];Ma, Xingyuan[1]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China;[3]Xiamen Univ, State Key Lab Marine Environm Sci, Xiamen, Peoples R China;[4]East China Univ Sci & Technol, Sch Math, Shanghai, Peoples R China;[5]Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China;[6]Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China

年份：2025

卷号：14

期号：1

外文期刊名：EMERGING MICROBES & INFECTIONS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001509777700001)】；

基金：We thank the Public Instrument Service Platform of State Key Laboratory of Bioreactor Engineering and the Research Centre of Analysis in this study.

语种：英文

外文关键词：Oral gut-targeted; rabies virus-like particles (RVLPs); mucosal immune vaccines; localized-release microparticles; LTB B subunit of heat-labile toxin (LTB); PLGA/Eudradit microparticle (EPLGA MPs)

摘要：Rabies, a fatal zoonotic infectious diseases caused by rabies virus (RABV) infection, still has a high incidence with no effective cure in many Asian countries, even though numerous commercial vaccines have been administered for decades. One of the most important reasons is the neglected that main reservoirs of RABV, such as many stray and wild animals, are inaccessible for effective vaccination, especially in natural wilderness environments. In this study, we developed a highly effective gut-targeted oral rabies vaccine (ORV), which containing the immunoadjuvant LTB by targeted administration of microparticles with local release in the intestine. Based on the virus like particles (RVLPs) were assembled by RABV glycoprotein (RVGP) and matrix protein (RVMP), the enterically released microparticles ELPGA MPs loaded with RVLPs and djuvant LTB (RVLPs + LTB/EPLGA MPs) were prepared and demonstrated the ability of intestinal targeting which released in a pH-dependent manner. Subsequently, in vivo immunoassay experiments showed that the levels of anti-RVLPs IgG, IFN-gamma and IL-4 were significantly higher in the RVLPs + LTB/EPLGA MPs groups than in the normal saline group or positive control group (R group) after intragastric administration. Moreover, higher levels of CD4+/CD8+ T cells ratios in the peripheral blood and sIgA in the intestines and feces of mice indicated that RVLPs + LTB/EPLGA MPs group elicited a stronger cellular immune response and mucosal immunity. In short, the novel oral vaccine is exploring valuable strategies of oral gut-targeted vaccines and promising to effectively prevent the spread of RABV among terrestrial carnivorous animals and human populations.